ASX Announcement

Imugene Receives $2.1m R&D Tax Refund

Sydney, Australia, 16 November 2026: Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is pleased to announce it has received its research and development (R&D) tax refund for the 2026 financial year, totaling A$2,145,157.

The refund is received as part of the Australian Government's R&D Tax Incentive, which provides companies engaging in appropriate and eligible activities with a refundable tax offset of up to 43.5%.

The refund received by Imugene will assist ongoing patient recruitment in the Bruton Tyrosine Kinase inhibitor (BTKi) combination cohort 3 to the Phase 1b basket study of azer-cel (azercabtagene zapreleucel).

For more information please contact:

General Investor Enquiries
shareholderenquiries@imugene.com

Connect with us on LinkedIn @Imugene Limited

Watch us on YouTube @ImugeneLimited

About Imugene (ASX: IMU)

Imugene is a clinical stage cell therapy company developing an allogeneic CAR T for blood cancers. Our lead asset is an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies.

Imugene is focused on developing azer-cel for patients with B-cell cancers whose disease has progressed on existing treatments, including CAR T and BTK inhibitors.

Release authorised by the Executive Chairman, Imugene Limited.